Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Metformin and acarbose improve glycemic control in type 2 diabetes
Última actualización 21 de agosto de 2026
Key finding
Metformin therapy was independently associated with higher triglycerides (TGs, β = 0.471, P = 0.003).
This study investigated the combined effects of metformin and acarbose on glycemic control in type 2 diabetes patients, revealing significant impacts of metformin on triglycerides and LDL cholesterol.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the combined effects of metformin and acarbose on glycemic control in type 2 diabetes patients, revealing significant impacts of metformin on triglycerides and LDL cholesterol.
Clinical relevance
Understanding the effects of these medications is crucial for optimizing treatment strategies in type 2 diabetes. The findings suggest that while metformin can improve certain lipid profiles, it may also lead to higher triglycerides and postprandial glucose levels, which could influence clinical decisions regarding diabetes management.
Keep in mind
Limited sample size may affect the generalizability of results. The study did not assess long-term outcomes of the interventions. Potential confounding factors were not fully controlled.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Yu A, Yinhui L, Nannan B, et al. The interactive effect of metformin and acarbose on glycemic control in patients with type 2 diabetes. Frontiers in Nutrition. 2022;9:861750. doi:10.3389/fnut.2022.861750
Efectos Principales
Metformin therapy was associated with an increase in triglycerides (β = 0.471, P = 0.003).
Metformin therapy was associated with an increase in 2-hour postprandial plasma glucose (β = 0.381, P = 0.046).
Metformin therapy was associated with a decrease in low-density lipoprotein cholesterol (β = -0.149, P = 0.013).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Acarbose, Metformin and Glucose iAUC (OGTT), Triglycerides, Very-low-density lipoprotein cholesterol.
This study contributes evidence to
Primary intervention
Acarbose
Primary outcomes
- Glucose iAUC (OGTT)
- Triglycerides
- Very-low-density lipoprotein cholesterol
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
698
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Metformin Therapies and Postprandial and OGTT Glucose
Evidencia relacionada
Relación de evidencia
Alpha-glucosidase inhibitors and Postprandial and OGTT Glucose
Guardar evidencia
Relación de evidencia
Metformin Therapies and Adipokine and Angiogenic Markers
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerVery-low-density lipoprotein cholesterol
Acarbose → Very-low-density lipoprotein cholesterol
Acarbose → Very-low-density lipoprotein cholesterol
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 71
- Positive
- ConsistencyScore™
- 75
- consistent
Estudios de apoyo: Basado en 6 estudios
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
Add to Evidence TrackerVery-low-density lipoprotein cholesterol
Metformin → Very-low-density lipoprotein cholesterol
Metformin → Very-low-density lipoprotein cholesterol
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Metformin increased triglycerides by 0.471 mmol/L (P = 0.003).
- Metformin increased 2-hour postprandial glucose by 0.381 mmol/L (P = 0.046).
- Metformin decreased LDL cholesterol by 0.149 mmol/L (P = 0.013).
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients currently undergoing treatment for glycemic control.
Tener en Cuenta
- Results may not apply to populations outside the study sample.
- The effects of acarbose were not significant in this study.
- Further research is needed to explore long-term impacts of these medications.
Entre Líneas
- Limited sample size may affect the generalizability of results.
- The study did not assess long-term outcomes of the interventions.
- Potential confounding factors were not fully controlled.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Metformin Therapies and Postprandial and OGTT Glucose, Metformin Therapies and Adipokine and Angiogenic Markers.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- 83
- Strong
- ImpactScore™
- 71
- Positive
- ConsistencyScore™
- 75
- consistent
Estudios de apoyo: Basado en 6 estudios
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 38
- Slightly Negative
- ConsistencyScore™
- 35
- mixed
Estudios de apoyo: Basado en 2 estudios
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Metformin Therapies Evidence Hub
All studies on Metformin Therapies
6 studies
intervention_hubContributes to Metformin Therapies evidence base.
Postprandial and OGTT Glucose Evidence Hub
All studies measuring Postprandial and OGTT Glucose
6 studies
outcome_hubMeasures Postprandial and OGTT Glucose as a key outcome.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
2 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Alpha-glucosidase inhibitors Evidence Hub
All studies on Alpha-glucosidase inhibitors
1 studies
intervention_hubContributes to Alpha-glucosidase inhibitors evidence base.
Very-low-density lipoprotein cholesterol Evidence Hub
All studies measuring Very-low-density lipoprotein cholesterol
1 studies
outcome_hubMeasures Very-low-density lipoprotein cholesterol as a key outcome.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Metformin and Glucose iAUC (OGTT)
Intervention: MetforminOutcome: Glucose iAUC (OGTT)
6 results
All studies on Metformin and Triglycerides
Intervention: MetforminOutcome: Triglycerides
2 results
All studies on Metformin
Intervention: Metformin
6 results
All studies on Acarbose
Intervention: Acarbose
1 results
All studies measuring Glucose iAUC (OGTT)
Outcome: Glucose iAUC (OGTT)
6 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Metformin Therapies improve postprandial and ogtt glucose?
Strong Evidence
Metformin Therapies may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Glucose iAUC (OGTT)
EvidenceScore™ Strong | EvidenceScore™ 82.8 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 8 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Alpha-glucosidase inhibitors improve postprandial and ogtt glucose?
Strong Evidence
Alpha-glucosidase inhibitors may improve Postprandial and OGTT Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
Glucose iAUC (OGTT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Metformin Therapies improve adipokine and angiogenic markers?
Strong Evidence
Metformin Therapies may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Population details are unavailable.
Does Alpha-glucosidase inhibitors improve adipokine and angiogenic markers?
Emerging Evidence
Current evidence does not show a clear benefit of Alpha-glucosidase inhibitors for Adipokine and Angiogenic Markers.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Triglycerides
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Carnosine shows little effect on cardiovascular outcomes in diabetesDietary Modulation of Gut Microbiota in PrediabetesVildagliptin and Metformin Improve Glycemic Control in Type 2 DiabetesEarly use of effective therapies may improve diabetes outcomesGlucose variability increases with age in type 2 diabetes patients
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.